Transdermal contraception and the renin-angiotensin-aldosterone system in premenopausal women

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 6, 2015, Pages F535-F540

  Odutayo, Ayodele ^a   Cherney, David ^b   Miller, Judith ^b   Ahmed, Sofia B ^c   Lai, Vesta ^b   Dunn, Sheila ^d   Pun, Nicole ^b   Moineddin, Rahim ^e   Hladunewich, Michelle A ^a,b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Contraceptive patch; Oral contraception; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSINOGEN; ESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; RENIN; CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CONTRACEPTION; CONTRACEPTIVE PATCH; CONTROLLED STUDY; FEMALE; HEMODYNAMICS; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; LOWER BODY NEGATIVE PRESSURE; MEAN ARTERIAL PRESSURE; ORAL CONTRACEPTION; ORTHOSTATIC STRESS; PLASMA RENIN ACTIVITY; PREMENOPAUSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRANSDERMAL CONTRACEPTION; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECTS; INTRADERMAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADULT; ANGIOTENSIN II; BLOOD PRESSURE; CASE-CONTROL STUDIES; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; PREMENOPAUSE; RENIN; RENIN-ANGIOTENSIN SYSTEM; YOUNG ADULT;

EID: 84929501565     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00602.2014     Document Type: Article

References (30)

1. Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM, Lansang MC, Stevanovic R, Fisher NDL, Hollenberg NK. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 28: 1988-1994, 2005.
2. Ahmed SB, Kang AK, Burns KD, Kennedy CRJ, Lai V, Cattran DC, Scholey JW, Miller JA. Effects of oral contraceptive use on the renal and systemic vascular response to angiotensin II infusion. J Am Soc Nephrol 15: 780-786, 2004.
3. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90: 3863-3870, 2005.
4. Chasan-Taber L, Willett WC, Manson JE, Spiegelman D, Hunter DJ, Curhan G, Colditz GA, Stampfer MJ. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94: 483-489, 1996.
5. Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, Eynatten von M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587-597, 2014.
6. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL. Biologic effects of transdermal estradiol. N Engl J Med 314: 1615-1620, 1986.
7. Chidambaram M, Duncan JA, Lai VS, Cattran DC, Floras JS, Scholey JW, Miller JA. Variation in the renin angiotensin system throughout the normal menstrual cycle. J Am Soc Nephrol 13: 446-452, 2002.
8. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 354: 2443-2451, 2006.
9. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369: 1892-1903, 2013.
10. Girndt J, Kramer P, Quellhorst E, Held K, Bohle A, Scheler F. [Oral contraceptives, hypertension and nephrosclerosis (author’s transl)]. Dtsch Med Wochenschr 101: 1246-1251, 1976.
11. Henzl MR, Loomba PK.; Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. J Reprod Med 48: 525-540, 2003.
12. Hirsch AT, Levenson DJ, Cutler SS, Dzau VJ, Creager MA. Regional vascular responses to prolonged lower body negative pressure in normal subjects. Am J Physiol Heart Circ Physiol 257: H219-H225, 1989.
13. Hladunewich MA, Kingdom J, Odutayo A, Burns K, Lai V, O’Brien T, Gandhi S, Zimpelmann J, Kiss A, Miller J, Cherney D. Postpartum assessment of the renin angiotensin system in women with previous severe, early-onset preeclampsia. J Clin Endocrinol Metab 96: 3517-3524,2011.
14. Kang AK, Duncan JA, Cattran DC, Floras JS, Lai V, Scholey JW, Miller JA. Effect of oral contraceptives on the renin angiotensin system and renal function. Am J Physiol Regul Integr Comp Physiol 280: R807-R813, 2001.
15. Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366: 2257-2266, 2012.
16. Ligniers BD, Basdevant A, Thomas G, Thalabard JC, Mercier-Bo-dard C, Conard J, Guyene TT, Mairon N, Corvol P, Guy-Grand B, Mauvais-Jarvis P, Sitruk-Ware R. Biological effects of estradiol-17 in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 62: 536-541, 1986.
17. Monster TB, Janssen WM, deJong PE, de Jong-van den Berg LT; Prevention of Renal and Vascular End Stage Disease Study Group. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Arch Intern Med 161: 2000-2005, 2001.
18. Moroni G, Quaglini S, Banfi G, Caloni M, Finazzi S, Ambroso G, Como G, Ponticelli C. Pregnancy in lupus nephritis. Am J Kidney Dis 40: 713-720, 2002.
19. Munkhaugen J, Lydersen S, Romundstad PR, Wideroe TE, Vikse BE, Hallan S. Kidney function and future risk for adverse pregnancy out-comes: a population-based study from HUNT II, Norway. Nephrol Dial Transplant 24: 3744-3750, 2009.
20. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559, 2008.
21. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213, 2012.
22. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting enzyme activity in postmenopausal women. Lancet 346: 89-90, 1995.
23. Ribstein J, Halimi JM, Cailar du G, Mimran A. Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 33: 90-95, 1999.
24. Riera M, Navas-Parejo A, Gomez M, Cerezo S.; [Malignant hypertension and irreversible kidney failure associated with oral contraception pills intake]. Nefrologia 24: 298-299, 2004.
25. Saji H, Yamanaka M, Hagiwara A, Ijiri R. Losartan and fetal toxic effects. Lancet 357: 363, 2001.
26. Schaefer C. Angiotensin II-receptor-antagonists: further evidence of fetotoxicity but not teratogenicity. Birth Defects Res A Clin Mol Teratol 67: 591-594, 2003.
27. Schunkert H, Danser AH, Hense HW, Derkx FH, Kürzinger S, Riegger GA. Effects of estrogen replacement therapy on the reninangiotensin system in postmenopausal women. Circulation 95: 39-45, 1997.
28. Seely EW, Walsh BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 33: 1190-1194, 1999.
29. van den Heuvel MW, van Bragt AJM, Alnabawy AKM, Kaptein MCJ. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72: 168-174, 2005.
30. Zech P, Rifle G, Lindner A, Sassard J, Blanc-Brunat N, Traeger J. Malignant hypertension with irreversible renal failure due to oral contraceptives. Br Med J 4: 326-327, 1975.